Akebia Ther

Yahoo Finance • 11 days ago

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted seven newly-hired employees opt... Full story

Yahoo Finance • last month

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted two newly-hired employees opti... Full story

Yahoo Finance • 2 months ago

Akebia GAAP EPS of $0.00 beats by $0.02, revenue of $62.47M beats by $15.23M

* Akebia press release [https://seekingalpha.com/pr/20192771-akebia-therapeutics-reports-second-quarter-2025-financial-results-and-recent-business] (NASDAQ:AKBA [https://seekingalpha.com/symbol/AKBA]): Q2 GAAP EPS of $0.00 beats by $0.02... Full story

Yahoo Finance • 3 months ago

Akebia Therapeutics (AKBA) Kidney Therapy Vafseo Gaining Market Share

Akebia Therapeutics, Inc. (NASDAQ:AKBA) is one of the best high-return penny stocks to buy now. On July 14, 2025, Akebia shared key updates during the H.C. Wainwright Kidney Conference, emphasizing the rollout of its oral anemia treatment... Full story

Yahoo Finance • 3 months ago

Catalyst Watch: Bank earnings rush, OPEC report, Tesla EVs get Grok, and Superman at the box office

[Wall Street sign in Lower Manhattan, NYC] georgeclerk Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. MO... Full story

Yahoo Finance • 3 months ago

Akebia Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference

CAMBRIDGE, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that Nik Grund, Chief C... Full story

Yahoo Finance • 3 months ago

Leerink Partners Reiterates a Buy Rating on Akebia Therapeutics (AKBA) With a $7 PT

Akebia Therapeutics, Inc. (NASDAQ:AKBA) is one of the 13 Stocks Under $5 With High Upside Potential. On May 29, Leerink Partners analyst Roanna Ruiz maintained a Buy rating on Akebia Therapeutics, Inc. (NASDAQ:AKBA) and set a price target... Full story

Yahoo Finance • 5 months ago

Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference 2025

CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that Akebia Executive Ma... Full story

Yahoo Finance • 7 months ago

Akebia Therapeutics Announces Poster Presentations at NKF Spring Clinical Meetings 2025

CAMBRIDGE, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will present d... Full story

Yahoo Finance • 7 months ago

Why Akebia Therapeutics Inc. (AKBA) Went Down On Thursday?

We recently published a list of Thursday’s 10 Worst-Performing Stocks. In this article, we are going to take a look at where Akebia Therapeutics Inc. (NASDAQ:AKBA) stands against other Thursday’s worst-performing stocks. Wall Street’s mai... Full story

Yahoo Finance • 7 months ago

Akebia Therapeutics Announces Pricing of Public Offering of Common Stock

CAMBRIDGE, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (“Akebia”) (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the pricing... Full story

Yahoo Finance • 7 months ago

Akebia Therapeutics Announces Proposed Public Offering of Common Stock

CAMBRIDGE, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (“Akebia”) (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it has... Full story

Yahoo Finance • 7 months ago

Akebia Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Discuss Recent Business Highlights

CAMBRIDGE, Mass., March 06, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the fourth quarter and full year ended December 31, 2024, on Thursday, March 13, 20... Full story

Yahoo Finance • 2 years ago

Akebia Therapeutics to Present at Piper Sandler Healthcare Conference

CAMBRIDGE, Mass., Nov. 20, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Execut... Full story

Yahoo Finance • 2 years ago

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q3 2023 Earnings Call Transcript

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q3 2023 Earnings Call Transcript November 8, 2023 Akebia Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.08, expectations were $-0.09. Operator: Good day and thank you for stand... Full story

Yahoo Finance • 2 years ago

Akebia Announces Swissmedic Approval of Vafseo® (vadadustat)

CAMBRIDGE, Mass., June 20, 2023 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced that the Swiss Agency for Therapeutic Products (Swissmedic) has granted marketing authorization for Vafseo® (vadadustat), an oral hyp... Full story

Yahoo Finance • 3 years ago

Akebia Therapeutics to Report Second Quarter Financial Results

Akebia to Host Conference Call to Provide Business Update CAMBRIDGE, Mass., July 26, 2022 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kid... Full story

Yahoo Finance • 3 years ago

AKBA FINAL DEADLINE FRIDAY: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Akebia Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important May 13 Deadline in Securities Class Action – AKBA

NEW YORK, May 10, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Akebia Therapeutics, Inc. (NASDAQ: AKBA) between June 28, 2018 and September 2, 2020, inclusive (... Full story

Yahoo Finance • 3 years ago

AKEBIA THERAPEUTICS, INC. (NASDAQ: AKBA) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Akebia Therapeutics, Inc. (NASDAQ: AKBA)

NEW YORK, May 10, 2022 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been file... Full story

Yahoo Finance • 3 years ago

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Akebia, Grab, and Celsius and Encourages Investors to Contact the Firm

NEW YORK, May 08, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Akebia Therapeutics, Inc.... Full story